OnScene study reports a higher percentage surviving to hospital discharge for patients 50 years or younger with refractory out-of-hospital cardiac arrest using prehospital extracorporeal versus conventional care. Editorial titled “Bringing Rapid Reperfusion to More Patients with Out-of-Hospital Cardiac Arrest” is linked.
Key points
Patients 50 years of age or younger with refractory out-of-hospital cardiac arrest.
Higher percentage surviving to hospital discharge with prehospital extracorporeal than with conventional care.
Sources
- Original post
- nej.md - Linked in the post
- nej.md - Linked in the post
Pelacarsen trial fails to reduce cardiovascular events
Pelacarsen, an Lp(a)-lowering drug, failed in the Lp(a)HORIZON trial to cut heart problems or stroke. The drug can lower lipoprotein(a) levels by 80% or more.
Key points
Lp(a)HORIZON trial showed no reduction in risk of heart problems and stroke.
Pelacarsen lowers lipoprotein(a) levels by 80% or more.
Sources
PROMISE rover launch to moon in 2028 announced
PROMISE rover will launch to the moon in late 2028 on a Blue Origin lander for an 18-month primary mission. The rover is modeled after Mars rovers and will drill and study lunar regolith and radiation near the south pole.
Key points
Launch date: late 2028, 18-month primary mission.
Launch vehicle: Blue Origin lander.
Mission role: scout Moon Base operations and prospect resources near the lunar south pole.
Project lead: James Keane, planetary scientist at JPL.